Literature DB >> 8014373

In vivo study of the role of muscarinic receptors in the parasympathetic control of rabbit colonic motility.

F Blanquet1, A Abysique, J Gonella.   

Abstract

The aim of the present study was to elucidate the role of the non-M1 muscarinic receptors, in the extrinsic and intrinsic nerve control of in vivo colonic motility. Experiments were performed on the proximal colon of anaesthetized rabbits. In this species, the parasympathetic innervation of the proximal colon originates from the vagus nerves. The action of methoctramine and 4-diphenyl-acetoxy-N-methylpiperidine methobromide (4-DAMP) was studied on excitatory junction potentials (EJPs), and on inhibitory junction potentials (IJPs) elicited in smooth muscle cells by stimulating parasympathetic efferents. The effects of the same drugs on spontaneous spiking activity were also investigated. The EJPs either decreased or disappeared after intra-arterial (i.a.) administration of 4-DAMP (45 pg to 450 ng). In the presence of 4-DAMP, further intravenous (i.v.) administration of pirenzepine (0.1 mg.kg-1) had facilitatory effects on the inhibitory pathway, i.e., after abolition of the EJPs, vagal stimulation elicited IJPs. With the highest dose of 4-DAMP, vagal stimulation immediately elicited IJPs the amplitude of which still increased after pirenzepine. In the presence of 4-DAMP, the spontaneous spike discharge was not noticeably altered. Methoctramine (0.37 to 75 micrograms, i.a. or 50 micrograms to 0.2 mg.kg-1, i.v.) increased the amplitude of the EJPs, whereas it decreased that of the IJPs. In addition, at the same doses, it either initiated or increased spike discharges that were not altered by pirenzepine up to 0.2 mg.kg-1, i.v. The so-called rebound excitation occurring after IJPs was not affected by methoctramine. No change in the EJP or IJP amplitude was observed with gallamine at sufficiently high doses to paralyse striated muscles (up to 3 mg.kg-1.h-1). It is concluded that the parasympathetic excitatory pathway to smooth muscle is blocked by 4-DAMP, whereas it is facilitated by methoctramine. 4-DAMP has no effect on the inhibitory pathway which is strongly depressed by methoctramine; however, the fact that these two drugs have opposite effects indicates that 4-DAMP and methoctramine may act on different muscarinic receptor subtypes. In addition, the facilitatory effects of pirenzepine on IJPs observed in animals pre-treated with 4-DAMP, indicates that the latter drug may act on non-M1 and non-M2 (presumably M3) muscarinic receptors. Methoctramine acts on non-M1 and non-M3 (presumably M2) receptors. The spike discharge induced by methoctramine is presumably due to an increased release of acetylcholine, and possibly also of a non-cholinergic transmitter which has excitatory effects on smooth muscle, the identification of which requires further investigations.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014373     DOI: 10.1016/0165-1838(94)90039-6

Source DB:  PubMed          Journal:  J Auton Nerv Syst        ISSN: 0165-1838


  4 in total

Review 1.  Nitric oxide and the pancreas: morphological base and role in the control of the exocrine pancreatic secretion.

Authors:  M D Yago; M Mañas; Z Ember; J Singh
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.

Authors:  Gregory D Scott; Allison D Fryer
Journal:  Chem Immunol Allergy       Date:  2012-06-26

3.  Interaction of human chagasic IgG with human colon muscarinic acetylcholine receptor: molecular and functional evidence.

Authors:  L Sterin-Borda; J C Goin; C R Bilder; G Iantorno; A C Hernando; E Borda
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

4.  Characterisation of colonic accommodation in Wistar Kyoto rats with impaired gastric accommodation.

Authors:  Vicente Martínez; Mikael Ryttinger; Marita Kjerling; Maria Astin-Nielsen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-02       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.